<?xml version='1.0' encoding='utf-8'?>
<document id="7074982"><sentence text="Pharmacokinetics and mode of action of tienilic acid."><entity charOffset="39-52" id="DDI-PubMed.7074982.s1.e0" text="tienilic acid" /></sentence><sentence text="A review of the absorption, distribution, metabolism and excretion of ticrynafen (tienilic acid) in 8 animal species, including man, is presented"><entity charOffset="70-80" id="DDI-PubMed.7074982.s2.e0" text="ticrynafen" /><entity charOffset="82-95" id="DDI-PubMed.7074982.s2.e1" text="tienilic acid" /><pair ddi="false" e1="DDI-PubMed.7074982.s2.e0" e2="DDI-PubMed.7074982.s2.e0" /><pair ddi="false" e1="DDI-PubMed.7074982.s2.e0" e2="DDI-PubMed.7074982.s2.e1" /></sentence><sentence text=" Although some species effects are apparent, ticrynafen absorption is essentially complete following oral administration" /><sentence text=" The compound is extensively bound to plasma proteins, primarily albumin" /><sentence text=" Consequently, tissue concentrations are generally lower than plasma concentrations" /><sentence text=" Plasma and whole body clearance of ticrynafen is rapid due both to metabolism and to extensive renal excretion of the compound and its metabolites" /><sentence text=" Male/female differences in renal excretion occur, with a subsequent effect on ticrynafen metabolism" /><sentence text=" Ticrynafen is an inhibitor of reabsorption of sodium and uric acid by the kidney"><entity charOffset="1-11" id="DDI-PubMed.7074982.s8.e0" text="Ticrynafen" /><entity charOffset="47-53" id="DDI-PubMed.7074982.s8.e1" text="sodium" /><entity charOffset="58-67" id="DDI-PubMed.7074982.s8.e2" text="uric acid" /><pair ddi="false" e1="DDI-PubMed.7074982.s8.e0" e2="DDI-PubMed.7074982.s8.e0" /><pair ddi="false" e1="DDI-PubMed.7074982.s8.e0" e2="DDI-PubMed.7074982.s8.e1" /><pair ddi="false" e1="DDI-PubMed.7074982.s8.e0" e2="DDI-PubMed.7074982.s8.e2" /><pair ddi="false" e1="DDI-PubMed.7074982.s8.e1" e2="DDI-PubMed.7074982.s8.e1" /><pair ddi="false" e1="DDI-PubMed.7074982.s8.e1" e2="DDI-PubMed.7074982.s8.e2" /></sentence><sentence text=" This inhibitory effect, within the renal tubular lumen, accounts for its diuretic and uricosuric activity and could account for its antihypertensive activity, although a direct effect has also been claimed" /><sentence text=" Ticrynafen is also a classical example of a competitive inhibitor of organic acid transport in the kidney and other organs" /><sentence text=" Much of the drug-drug interaction involving ticrynafen is understandable due to its effect on transport" /><sentence text=" However, potentiation of anticoagulant activity appears to involve some direct effects upon warfarin metabolism although ticrynafen, in general, is not an enzyme inducer or inhibitor" /><sentence text=" Toxicity of ticrynafen is low in all animal species" /><sentence text="" /></document>